Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 6/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.42 |
| ▸ | GABRP | O00591 | 5/20 | 0.42 |
| ▸ | GABRD | O14764 | 5/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.42 |
| ▸ | GABRE | P78334 | 5/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943243 | 0.90 | ALDH1A1 (0.40) | CNR2GABRA2GABRA1GABRG2GABRB3 | |
| SCHEMBL2943248 | 0.90 | ALDH1A1 (0.40) | CNR2GABRA2GABRA1GABRG2GABRB3 | |
| SCHEMBL2950960 | 0.90 | ALDH1A1 (0.40) | CNR2GABRA2GABRA1GABRG2GABRB3 | |
| SCHEMBL4805906 | 0.87 | ALDH1A1 (0.43) | CNR2GABRA2GABRA1GABRG2GABRB3 | |
| SCHEMBL2945250 | 0.86 | GABRA1 (0.43) | CNR2GABRA2GABRA1GABRG2GABRB3 | |
| SCHEMBL2946795 | 0.86 | ALKBH1 (0.41) | FSCN1PTGDR2PTGER1 | |
| SCHEMBL2946889 | 0.84 | FSCN1 (0.42) | FSCN1PTGDR2F2RL3 | |
| SCHEMBL2945282 | 0.83 | FSCN1 (0.41) | NPC1FSCN1PTGDR2F2RL3 | |
| SCHEMBL2949469 | 0.83 | FSCN1 (0.42) | FSCN1 | |
| SCHEMBL4811995 | 0.81 | FSCN1 (0.39) | MAPTFSCN1PTGDR2F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558611-B1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
| US-7368571-B2 | HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use | PFIZER INC (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7135482-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1558611-A2 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004039803-A2 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | IMPDH1, POLA1, POLB | CNR2 4649/4885GABRA2 2921/4885GABRA1 1833/4885 |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | CNR2 4607/4885GABRA2 2664/4885GABRA1 2018/4885 |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | CNR2 4653/4885GABRA2 2666/4885GABRA1 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.